Home
News
- 1 Eli Lilly And Co. (LLY) stock price experienced the bears’ dominance last week.
- 2 In year-to-date (YTD) price analysis, LLY stock price rose over 25%, opposing recent bearish performance.
Eli Lilly And Co. (NYSE: LLY) stock price lost $3.62 in the last 5 days of trading and showed a 1.49% price decline. This bearish trend in the stock price is following for the last 1 month, which further shows a 2.14% price drop.
However, an average trading volume activity can be seen in LLY stock price where majorly bears have shown their dominance.
According to TradingView, a web-based social network for traders, there are 440 stocks listed under the pharmaceuticals: major industry. All these stocks experienced more than 6 Million of volume in a day while their market cap is nearly $3.57 Trillion.
Along with LLY share price, Takeda Pharmaceutical Co Ltd (NYSE: TAK), Walgreens Boots Alliance Inc. (NASDAQ: WBA), and ATAI Life Sciences NV (NASDAQ: ATAI) also showed over 1.40% of weekly price decline.
LLY Stock Price Analysis
Near the weekend, bulls started showing interest in Eli Lilly And Co. (LLY) stock price which showed a 0.77% price rise on July 28, 2023, Friday. The opening price of LLY stock in Friday’s trading session was $455.13, which added $3.38 and closed at $458.48. The stock traded in between the price range of $459.57 to $451.78, as per the data sourced from TradingView.
With the recent bullish trend, the RSI of LLY stock started moving upwards. The upside move brought LLY share price to trade slightly above its 20-day moving average. Since the last earnings and revenue report was released late in April 2023, LLY share price made a bullish graph.
The 1-year price target set by the analysts is at $479.49, up by over 4% from the recent closing price of LLY shares. Their maximum price estimate is at $565.00 whereas the minimum estimate is at $300.00. Moreover, in the past 3-months, analysts suggested a “buy” rating for Eli Lilly and Company.
The Financials Highlight of Eli Lilly and Company
Eli Lilly And Co. (NYSE: LLY), an American pharmaceutical company, has a market cap of nearly $435.22 Billion. According to its Q1 2023 earnings and revenue report, its net income is $1.34 Billion. LLY price-to-sales ratio is 14.84 while the company has an Enterprise Value to EBITDA ratio of 51.06.
LLY dividends are paid quarterly. The next dividend per share is expected to be $1.13 and as of today, the Dividend Yield (TTM)% is 0.93%.
LLY earnings per share (EPS) for Q1 2023 is $1.62 whereas the estimation was at $1.73. The revenue for the same period amounts to $6.96 Billion despite the estimated figure of $6.86 Billion. For upcoming Q2 2023, the estimated EPS is $1.98 while the revenue is expected to reach $7.58 Billion.
Disclaimer
The views and opinions stated by the author, or any people named in this article, are for informational ideas only and do not establish financial, investment, or other advice. Investing in or trading crypto or stock comes with a risk of financial loss.
Steve Anderson is an Australian crypto enthusiast. He is a specialist in management and trading for over 5 years. Steve has worked as a crypto trader, he loves learning about decentralisation, understanding the true potential of the blockchain.
